Helix BioPharma Corp. (TSE:HBP – Get Free Report) shares hit a new 52-week low during trading on Wednesday . The company traded as low as C$1.10 and last traded at C$1.10, with a volume of 44539 shares traded. The stock had previously closed at C$1.17.
Helix BioPharma Price Performance
The stock’s 50 day moving average price is C$1.64 and its two-hundred day moving average price is C$1.67. The stock has a market cap of C$84.02 million, a price-to-earnings ratio of -27.50 and a beta of 0.72. The company has a quick ratio of 1.03, a current ratio of 0.45 and a debt-to-equity ratio of 2.44.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Featured Stories
- Five stocks we like better than Helix BioPharma
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
